血清 VEGF 水平与肝癌患者的预后相关：一项荟萃分析。
Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis.
机构信息
First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China; ; The Collaborative Research (CORE) Group, Sydney, Australia.
First Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing 210029, China;
出版信息
Hepatobiliary Surg Nutr. 2013 Aug;2(4):209-15. doi: 10.3978/j.issn.2304-3881.2013.06.07.
Abstract
BACKGROUND
Hepatocellular carcinoma (HCC) is a highly vascular tumor that expresses vascular endothelial growth factor (VEGF). Various studies have evaluated the prognostic value of VEGF levels in HCC, but yielded conflicting results.
METHODS
Electronic databases updated to June 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between serum VEGF level and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed.
RESULTS
We performed a meta-analysis of 11 studies that evaluated the correlation between serum VEGF level and survival in patients with HCC. Combined hazard ratios suggested that serum VEGF level had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.88, 95% confidence interval (CI): 1.46-2.30], and disease free survival (DFS) (HR=2.27, 95% CI: 1.55-2.98) in patients with HCC. No significant heterogeneity was observed among all studies.
CONCLUSIONS
Serum high VEGF level indicates a poor prognosis for patients with hepatocellular carcinoma.
摘要
背景
肝细胞癌（HCC）是一种高度血管化的肿瘤，表达血管内皮生长因子（VEGF）。多项研究评估了 HCC 患者 VEGF 水平的预后价值，但结果存在争议。
方法
检索至 2013 年 6 月的电子数据库，以寻找相关研究。对定量评估 HCC 患者血清 VEGF 水平与生存关系的合格研究进行荟萃分析。汇总并定量分析生存数据。
结果
我们对 11 项评估 HCC 患者血清 VEGF 水平与生存相关性的研究进行了荟萃分析。合并风险比表明，血清 VEGF 水平对 HCC 患者的总生存（OS）[风险比（HR）=1.88，95%置信区间（CI）：1.46-2.30]和无病生存（DFS）（HR=2.27，95%CI：1.55-2.98）有不利影响。所有研究之间均无显著异质性。
结论
血清高 VEGF 水平提示 HCC 患者预后不良。
相似文献
1
Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis.血清 VEGF 水平与肝癌患者的预后相关：一项荟萃分析。
Hepatobiliary Surg Nutr. 2013 Aug;2(4):209-15. doi: 10.3978/j.issn.2304-3881.2013.06.07.
2
Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis.血管内皮生长因子表达在肝癌组织中的预后意义：一项荟萃分析。
Hepatobiliary Surg Nutr. 2013 Jun;2(3):148-55. doi: 10.3978/j.issn.2304-3881.2013.06.06.
3
TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis.TP53 基因突变与肝癌患者预后不良相关：荟萃分析证据。
Hepatobiliary Surg Nutr. 2013 Oct;2(5):260-5. doi: 10.3978/j.issn.2304-3881.2013.07.06.
4
Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis.TP53 表达对肝细胞癌患者预后的意义：一项荟萃分析。
Hepatobiliary Surg Nutr. 2014 Feb;3(1):11-7. doi: 10.3978/j.issn.2304-3881.2014.01.03.
5
VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis.血管内皮生长因子与前列腺癌患者的不良生存相关：一项荟萃分析。
Transl Androl Urol. 2013 Jun;2(2):99-105. doi: 10.3978/j.issn.2223-4683.2013.06.03.
6
Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis.血管内皮生长因子A表达在胃癌中的预后价值：一项荟萃分析
Tumour Biol. 2014 Mar;35(3):2787-93. doi: 10.1007/s13277-013-1371-1.
7
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.胃癌中血管内皮生长因子免疫组化表达的预后意义：一项荟萃分析。
Mol Biol Rep. 2012 Oct;39(10):9473-84. doi: 10.1007/s11033-012-1812-8. Epub 2012 Jun 23.
8
TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.TP53免疫组化表达与肝细胞癌的不良预后相关：一项荟萃分析的证据
Tumour Biol. 2014 Feb;35(2):1653-9. doi: 10.1007/s13277-013-1228-7.
9
VEGF-C expression is associated with the poor survival in gastric cancer tissue.血管内皮生长因子-C（VEGF-C）的表达与胃癌组织的不良预后相关。
Tumour Biol. 2014 Apr;35(4):3377-83. doi: 10.1007/s13277-013-1445-0. Epub 2013 Dec 5.
10
Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.血管内皮生长因子（VEGF）表达在骨肉瘤中的预后意义：一项荟萃分析。
Tumour Biol. 2014 Jan;35(1):155-60. doi: 10.1007/s13277-013-1019-1. Epub 2013 Aug 2.
引用本文的文献
1
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.血管生成与肝细胞癌：从分子机制到系统治疗。
Medicina (Kaunas). 2023 Jun 9;59(6):1115. doi: 10.3390/medicina59061115.
2
Genetic Analysis of Platelet-Related Genes in Hepatocellular Carcinoma Reveals a Novel Prognostic Signature and Determines PRKCD as the Potential Molecular Bridge.肝细胞癌中血小板相关基因的遗传分析揭示了一种新的预后特征，并确定PRKCD为潜在的分子桥梁。
Biol Proced Online. 2022 Dec 3;24(1):22. doi: 10.1186/s12575-022-00185-9.
3
All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma.条条大路通组织蛋白酶：组织蛋白酶在非酒精性脂肪性肝炎诱导的肝细胞癌中的作用
Biomedicines. 2022 Sep 21;10(10):2351. doi: 10.3390/biomedicines10102351.
4
A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome.一种与肝细胞癌免疫微环境和生存结果相关的新型血管生成相关预后标志物。
Int J Gen Med. 2022 Jan 7;15:311-323. doi: 10.2147/IJGM.S349210. eCollection 2022.
5
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.索拉非尼与二甲双胍联合治疗肝细胞癌患者中 VEGF 和 HIF-1α 的预后意义。
J Gastrointest Cancer. 2021 Mar;52(1):269-279. doi: 10.1007/s12029-020-00389-w.
6
Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.VEGFs/VEGFR-1 信号通路在调节肿瘤侵袭中的作用及其抑制作用：不同转移性癌症模型的实验证据。
Int J Mol Sci. 2020 Feb 18;21(4):1388. doi: 10.3390/ijms21041388.
7
A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.一项评估替沃扎尼（tivozanib）在不可切除的晚期肝细胞癌患者中的多中心 1b/2 期研究。
Br J Cancer. 2020 Mar;122(7):963-970. doi: 10.1038/s41416-020-0737-6. Epub 2020 Feb 10.
8
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics.血小板与肝细胞癌：从实验室到临床的桥梁
Cancers (Basel). 2019 Oct 15;11(10):1568. doi: 10.3390/cancers11101568.
9
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.经动脉化疗栓塞术治疗肝癌的进展
Radiology. 2019 Dec;293(3):704-706. doi: 10.1148/radiol.2019192090. Epub 2019 Oct 15.
10
Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC).肝细胞癌（HCC）肝靶向治疗及与全身治疗联合应用的现状
Cancers (Basel). 2019 Jul 31;11(8):1085. doi: 10.3390/cancers11081085.
本文引用的文献
1
Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.促红细胞生成素刺激剂（ESAs）治疗癌症相关性贫血时发生静脉血栓栓塞的风险：一项随机对照试验的荟萃分析
Chin Clin Oncol. 2012 Dec;1(2):19. doi: 10.3978/j.issn.2304-3865.2012.12.10.
2
V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.V-CLIP：将血浆血管内皮生长因子纳入新的评分系统，以对晚期肝细胞癌患者进行临床试验分层。
Cancer. 2011 Jun 1;117(11):2478-88. doi: 10.1002/cncr.25791. Epub 2010 Dec 14.
3
Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.COX-2 表达对非小细胞肺癌患者预后的预测价值：系统评价和荟萃分析。
J Thorac Dis. 2013 Feb;5(1):40-7. doi: 10.3978/j.issn.2072-1439.2013.01.02.
4
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.胃癌中血管内皮生长因子免疫组化表达的预后意义：一项荟萃分析。
Mol Biol Rep. 2012 Oct;39(10):9473-84. doi: 10.1007/s11033-012-1812-8. Epub 2012 Jun 23.
5
Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.血清血管内皮生长因子作为预测晚期肝细胞癌患者肝动脉灌注化疗反应和生存的指标。
J Gastroenterol. 2012 Jun;47(6):686-95. doi: 10.1007/s00535-012-0555-6. Epub 2012 Mar 1.
6
High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma.肝切除术后血清血管内皮生长因子水平升高与肝细胞癌预后不良相关。
Hepatogastroenterology. 2009 Jul-Aug;56(93):1122-6.
7
Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.血管内皮生长因子表达在肺癌患者中的预后价值：一项荟萃分析的系统评价
J Thorac Oncol. 2009 Sep;4(9):1094-103. doi: 10.1097/JTO.0b013e3181a97e31.
8
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.血管内皮生长因子在肝细胞癌中的预后作用：系统评价与荟萃分析
Br J Cancer. 2009 May 5;100(9):1385-92. doi: 10.1038/sj.bjc.6605017.
9
Immunotherapy of HCC.肝癌的免疫疗法。
Rev Recent Clin Trials. 2008 Jan;3(1):31-9. doi: 10.2174/157488708783330549.
10
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.血清血管内皮生长因子水平高预示肝细胞癌射频消融术后预后不良：肿瘤生物标志物在消融治疗中的重要性。
Ann Surg Oncol. 2007 Jun;14(6):1835-45. doi: 10.1245/s10434-007-9366-z. Epub 2007 Apr 4.
Zotero 插件